Carmustine wafers: Localized delivery of chemotherapeutic agents in CNS malignancies

Expert Review of Anticancer Therapy

Volumn 8, Issue 3, 2008, Pages 343-359

  Lin, Steven H ^a   Kleinberg, Lawrence R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplastic astrocytoma; BCNU; Brain tumors; Carmustine; Chemoradiotherapy; Gliadel Wafer; Glioblastoma; Interstitial chemotherapy; Polymer

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; 6 O BENZYLGUANINE; ANTICONVULSIVE AGENT; CAMPTOTHECIN; CANCER VACCINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; ETANIDAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LACTACYSTIN; LOMUSTINE; MINOCYCLINE; MITOXANTRONE; NITROSOUREA DERIVATIVE; PLACEBO; POLYMER; PROCARBAZINE; STEROID; TEMOZOLOMIDE; TIRAPAZAMINE; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; ATAXIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN ABSCESS; BRAIN CYST; BRAIN EDEMA; BRAIN METASTASIS; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; CYTOTOXICITY; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GLIOBLASTOMA; GLIOMA; HEALING IMPAIRMENT; HUMAN; IMMUNOMODULATION; INFECTION; LEUKOPENIA; LUNG FIBROSIS; LUNG INFILTRATE; LUNG TOXICITY; MEDULLOBLASTOMA; MENINGITIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; SEIZURE; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DELAYED-ACTION PREPARATIONS; GLIOMA; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL;

EID: 45249110397     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.343     Document Type: Article

References (78)

1. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J. Clin. Oncol. 24(8), 1253-1265 (2006).
2. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64(19), 6892-6899 (2004).
3. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8), 2585-2597 (1993).
4. Gaspar LE, Fisher BJ, Macdonald DR et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. Biol. Phys. 24(1), 55-57 (1992).
5. Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/ or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49(3), 333-343 (1978).
6. Sandberg-Wollheim M, Malmstrom P, Stromblad LG et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 68(1), 22-29 (1991).
7. Brem H, Mahaley MS Jr, Vick NA et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 74(3), 441-446 (1991).
8. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
9. Lohani S, O'Driscoll BR, Woodcock AA. 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood. Chest 126(3), 1007 (2004).
10. Shen YC, Chiu CF, Chow KC, Chen CL, Liaw YC, Yeh SP. Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-β1 and cyclooxygenase-2. Bone Marrow Transplant. 34(7), 609-614 (2004).
11. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311), 1011-1018 (2002).
12. Dang W, Daviau T, Brem H. Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Pharm. Res. 13(5), 683-691 (1996).
13. Able CM, Mills MD, McNeese MD, Hogstrom KR. Evaluation of a total scalp electron irradiation technique. Int. J. Radiat. Oncol. Biol. Phys. 21(4), 1063-1072 (1991).
14. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin. Pharmacokinet. 41(6), 403-419 (2002).
15. Domb AJ, Rock M, Perkin C, Yipchuck G, Broxup B, Villemure JG. Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain. Biomaterials 16(14), 1069-1072 (1995).
16. Grossman SA, Reinhard C, Colvin OM et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J. Neurosurg. 76(4), 640-647 (1992).
17. Fung LK, Shin M, Tyler B, Brem H, Saltzman WM. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res. 13(5), 671-682 (1996).
18. Fung LK, Ewend MG, Sills A et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclo phosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 58(4), 672-684 (1998).
19. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. 53(2), 329-333 (1993).
20. Buahin KG, Brem H. Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. J. Neurooncol. 26(2); 103-110 (1995).
21. Brem H, Piantadosi S, Barger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345(8956), 1008-1012 (1995).
22. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-1oaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant ghomas: Phase I trial. J. Neurooncol. 26(2), 111-123 (1995).
23. Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41(1), 44-48; discussion 48-49 (1997).
24. Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro. Oncol. 5(2), 79-88 (2003).
25. Westpbal M, Ram Z, Riddle V, Hilt D, Bortey E; Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: longterm follow-up of a multicenter controlled trial. Acta Neurochir. (Wien). 148(3), 269-275; discussion 275 (2006).
26. Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev. Anticancer Ther. 6(8), 1187-1204 (2006).
27. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
28. Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J. Biomed. Mater. Res. 23(2), 253-266 (1989).
29. Brem H, Tamargo RJ, Olivi A et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg. 80(2), 283-290 (1994).
30. Kleinberg LR, Weingart J, Burger P et al. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest. 22(1), 1-9 (2004).
31. Engelhard HH. Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg. Neurol. 53(3), 220-224 (2000).
32. McGirt MJ, Villavicencio AT, Bulsara KR, Friedman HS, Friedman AH. Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. J. Neurosurg. 96(5), 941-945 (2002).
33. Lawson HC, Sampath P, Bohan E et al. Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J. Neurooncol. 83(1), 61-70 (2007).
34. Kaal EC, Vecht CJ. The management of brain edema in brain tumors. Curr. Opin. Oncol. 16, 593-600 (2004).
35. Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother. Pharmacol. 39, 383-389 (1997).
36. Olivi A, Grossman SA, Tatter S et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J. Clin. Oncol. 21(9), 1845-1849 (2003).
37. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J. Clin. 49(1), 8-31 (1999).
38. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494-500 (1990).
39. Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17), 1485-1489 (1998).
40. Ewend MG, Williams JA, Tabassi K et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res. 56(22), 5217-5223 (1996).
41. Ewend MG, Sampath P, Williams JA, Tyler BM, Brem H. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 43(5), 1185-1193 (1998).
42. Ewend MG, Brent S, Gilbert M et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin. Cancer Res. 13(12), 3637-3641 (2007).
43. Laws ER Jr, Morris AM, Maartens N. Gliadel for pituitary adenomas and craniopharyngiomas. Neurosurgery 53(2), 255-269; discussion 259-260 (2003).
44. Park MC, Weaver CE Jr, Donahue JE, Sampath P. Intracavitary chemotherapy (Gliadel)i for recurrent esthesioneuroblastoma: case report review of the literature. J. Neurooncol. 77(1), 47-51 (2006).
45. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-l-nitrosourea. Cancer Res. 54(14), 3793-3799 (1994).
46. Mitchell RB, Dolan ME. Effect of temozolomide and dacarbazine on 06-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol. 32(1), 59-63 (1993).
47. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity an apoptosis induced by alkylating agents. DNA Repair 6(8), 1079-1099 (2007).
48. Gururangan S, Cokgor L, Rich JN et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro. Oncol. 3(4), 246-250 (2001).
49. Heery CR, Desjardins A, Quinn JA et al. Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. Proc. Am. Soc. Clin. Oncol. 24(Suppl. 18), 11504 (2006).
50. Asher AL. Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma. Proc. Am. Assoc. Neurol. Surg. 14, 42860 (2007).
51. La Rocca RV, Hodes J, Villanueva WG et al. A Phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone, surgery with carmustine (BCNU) wafer insertion. Proceedings of the 11th Scientific Meeting of the Society for Neuro-Oncology. Orlando, Florida, USA, 16-19 November, 2006 (Abstract TA-28).
52. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanadocha V. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
53. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl Acad. Sci. USA 87, 5368-5372 (1990).
54. Rabik CA, Njoku MC, Dolan ME. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat. Rev. 32, 261-276 (2006).
55. Rhines LD, P. Sampath, Dolan ME, Tyler BM, Brem H, Weingart J. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 60, 6307-631 (2000).
56. Weingart J, Grossman SA, Carson KA et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. Clin. Oncol. 25, 399-404 (2007).
57. Thompson RC, Pardoll DM, Jaffee EM et al. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunother. Emphasis Tumor Immunol. 19, 405-413 (1996).
58. Ewend MG, Thompson RC, Anderson R et al. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous systern. J. Immunother. 23, 438-448 (2000).
59. Sampath P, Hanes J, DiMeco F et al. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res. 59, 2107-2114 (1999).
60. Raza SM, Pradilla G, Legnani FG et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin. Biol. Ther. 5, 477-494 (2005).
61. Yuan X, Tabassi K, Williams JA. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma. Radiat. Oncol. Investig. 7, 218-230 (1999).
62. Williams JA, Dillehay LE, Tabassi K, Sipos E, Fahlman C, Brem H. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J. Neurooncol 32, 181-192 (1997).
63. Doiron A, Yapp DT, Olivares M, Zhu JX, Lehnert S. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine. Cancer Res. 59, 3677-3681 (1999).
64. Li Y, Owusu A, Lehnert S. Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 58, 519-527 (2004).
65. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res. 25, 3825-3831 (2005).
66. Pradilla G, Legnani FG, Petrangolini G et al. Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. Neurosurgery 57, 1032-1040; discussion 1032-1040 (2005).
67. Yapp, DT, Lloyd DK, Zhu J, Lehnert S. Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device. Radiother. Oncol. 53, 77-84 (1999).
68. Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int. J. Cancer 62, 605-609 (1995).
69. Olivi A, Ewend MG, Utsuki T et al. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother. Pharmacol. 39, 90-96 (1996).
70. Sheleg SV, Korotkevich EA, Zhavrid EA, Muravskaya GV, Smeyanovich AF, Shanko YG. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J. Neurooncol. 60, 53-59 (2002).
71. Judy KD, Olivi A, Buahin KG et al. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J. Neurosurg. 82, 481-486 (1995).
72. Legnani FG, Pradilla G, Thai QA et al. Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers. J. Neurooncol. 77, 225-232 (2006).
73. Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma J. Neurosurg. 82, 635-640 (1995).
74. DiMeco F, Li KW, Tyler BM, Wolf AS, Brem H, Olivi A. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J. Neurosurg. 97, 1173-1178 (2002).
75. Sampadi P, Rhines; LD, DiMeco F, Tyler BM, Park MC, Brem H. Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma. J. Neurooncol. 80, 19-17 (2006).
76. Bremn S, Tyler B, Li K et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother. Pharmacol. 60, 643-650 (2007).
77. Fournier E, Passirani C, Vonarbourg A et al. Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. Int J Pharm. 268, 31-35 (2003).
78. Lesniak SM, Brem H. Targeted therapy for brain tumours. Nat. Rev. Drug Discov. 3(6), 499-508 (2004).